Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy v
about
Expense and benefit of neoadjuvant treatment in squamous cell carcinoma of the esophagusNeoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysisPreoperative therapy in locally advanced esophageal cancerReevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials Over the Past 20 YearsCurrent Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan.Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS)Chemotherapy as a component of multimodal therapy for gastric carcinomaHistological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.Neoadjuvant treatment of esophageal cancer.RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma.Undervalued criteria in the evaluation of multimodal trials for upper GI cancers.Multimodality management of esophageal cancer.Interobserver reproducibility of diffusion-weighted MRI in monitoring tumor response to neoadjuvant therapy in esophageal cancer.FDG-PET parameters as prognostic factor in esophageal cancer patients: a review.Esophageal adenocarcinoma and obesity: peritumoral adipose tissue plays a role in lymph node invasion.Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma.Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression.Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancerThe predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus.(18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response.The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinomaRecurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response?The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer.Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinomaTreatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy.Multimodality approach for locally advanced esophageal cancer.Neoadjuvant treatment for esophageal squamous cell carcinoma.State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment.Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.Remnant lymph node metastases after neoadjuvant therapy and surgery in patients with pathologic T0 esophageal carcinoma impact on prognosis: A systematic review and meta-analysisNovel EGFR-targeted strategy with hybrid peptide against oesophageal squamous cell carcinoma.Prognosis of surgery combined with different adjuvant therapies in esophageal cancer treatment: a network meta-analysis.Predictive factors in the evaluation of treatment response to neoadjuvant chemoradiotherapy in patients with advanced esophageal squamous cell cancer.Current management of esophageal squamous-cell carcinoma in Japan and other countries.Chemotherapy Alone is an Appropriate Preoperative Therapy for Locally Advanced Esophageal Cancer.Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.F-18-FDG and C-11-Choline Positron Emission Tomography in Human Esophago-Gastric Cancer: Prediction of Response to Therapy.
P2860
Q24796779-D0D15010-6845-454B-B527-C5CFE5F25843Q24797571-801777C1-4701-4F2E-8A9C-116500A7E89DQ28070310-85A0FC5A-F098-4BF3-BFDE-18EB98F6EF11Q28081365-7623A365-47F4-412D-940D-4240200D5F76Q30244382-CFCB5E16-6198-4F3F-81BC-A4DC00259C78Q33387427-2021355D-AA31-4054-B5CD-CD73D976D912Q33867249-0E1563AB-B8E8-4254-8125-BD5A2FF12DC0Q33970074-75A87310-0C1E-4621-9921-7063C5755375Q34063710-31391B78-707F-4CAA-B650-89A269B405D9Q34298027-2E571B37-C7A8-40D5-8ECB-E28621F8A0E9Q34699973-8EC7728B-4218-4A35-A3CC-CE672A883004Q34981111-429B4395-9B8F-4EC7-B3ED-36F73E36B6E4Q35139999-D2D66759-3686-4A97-BECC-DBB9DBC8A96FQ35332601-CE758E77-4D7F-48DA-8DDE-CEB7F7C1B92FQ35793761-3F9BD3D1-70AA-49D5-BC6A-AA0485ACEA1CQ35835123-3DB5EC8D-F853-4182-9EC8-9262F752D7F0Q36057115-CD0EAC60-BD55-4086-B79E-5765E558ED09Q36392390-629F6F96-C388-4EBA-9CC5-446363C45972Q36427789-9F6ADB74-1B1E-4352-8D94-0D88FA5567BCQ36609800-5669C079-A22B-4946-805E-F9F7D7E66C9CQ36610597-E3E7AB73-FD1D-4666-BC12-935026F4B1AEQ36611842-4AA15BAD-17EB-4EC0-B891-BFC1391CAE94Q36613626-048D75D1-E39F-4A77-A41B-72472E6694EAQ36846116-4BA13CE8-C5C2-47A0-8202-875AB5042AE9Q37076617-4276581B-DB15-42C0-A4E9-A283C41A6C5CQ37439912-2D0C9FDB-3867-4318-88C4-FE32A049AA55Q37580437-7F381122-1ED5-492E-B9CC-DE3E03D2812EQ37612343-71D70DD9-3D23-4713-ABB6-2F744AFEC4BFQ38060114-71267355-3768-4E57-AAB4-1A35AAB0691FQ38212234-B6A31CF1-1342-4D74-9DA9-618E21ECA83BQ38340518-CCF29300-2AC5-4AEE-BB9C-5898B2B62289Q38636439-A300274C-11D3-4F20-BE14-990ED4D80C65Q38704657-9D90B41E-EDAC-4785-B8EF-301C687727FAQ38787773-8E26E55B-B77E-4C52-B832-AC889D44BC8CQ41055901-1FA9FA53-A0A7-4E4A-B099-3A29D2B26E00Q41202483-D30E74E6-B78B-4927-8B6B-F079C2E2836DQ42113341-71E639E3-EB57-4DB3-B8A7-C810A77DA3B7Q45753175-FC83AFAE-4E1D-4FAA-A5EA-01E7E4ABCAD4Q46770169-79E9FE9B-1EFF-447D-8549-93F6DDCE09AAQ47098382-CDEC5E78-91CF-4E85-AECE-1BC2035695B7
P2860
Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy v
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Only pathologic complete respo ...... of preoperative chemotherapy v
@en
Only pathologic complete respo ...... of preoperative chemotherapy v
@nl
type
label
Only pathologic complete respo ...... of preoperative chemotherapy v
@en
Only pathologic complete respo ...... of preoperative chemotherapy v
@nl
prefLabel
Only pathologic complete respo ...... of preoperative chemotherapy v
@en
Only pathologic complete respo ...... of preoperative chemotherapy v
@nl
P2093
P1433
P1476
Only pathologic complete respo ...... of preoperative chemotherapy v
@en
P2093
Merigliano S
Peracchia A
Zaninotto G
P304
P356
10.1002/1097-0142(20010601)91:11<2165::AID-CNCR1245>3.3.CO;2-8
P407
P577
2001-06-01T00:00:00Z